Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in five upcoming investor and scientific conferences in May 2022. Dr. Kishor Bhatia will present at the 9th Drug Discovery Strategic Summit on May 9, discussing synthetic lethality of drug candidates. CEO Panna Sharma will speak at four conferences, including the Strategic Investment Conference on May 13 and MedVentures Conference on May 18. Lantern is leveraging its RADR^® AI platform for oncology drug development.

Lantern Pharma (NASDAQ: LTRN) reported Q1 2022 financial results, revealing $65.2 million in cash and equivalents. The company utilizes its RADR^® A.I. platform, which surpassed 20 billion data points, enhancing drug discovery capabilities. The HARMONIC™ Phase 2 trial for LP-300 is expected to enroll patients in Summer 2022. Lantern plans to submit an IND for LP-184 by Q3 2022, targeting solid tumors. R&D expenses increased to $2.7 million from $1.3 million year-over-year. A net loss of $4.1 million was recorded, up from $2.5 million in Q1 2021.

Lantern Pharma (NASDAQ: LTRN) announced Dr. Maria L. Maccecchini as a nominee for its Board of Directors during the Annual Meeting on June 8, 2022. Dr. Maccecchini, a seasoned biopharmaceutical executive, brings decades of experience, particularly in neurodegenerative diseases. Concurrently, Leslie W. Kreis, Jr. will not seek reelection. Lantern's President, Panna Sharma, emphasized Dr. Maccecchini's potential contributions to ongoing clinical trials. Lantern is focused on utilizing its RADR^® platform to enhance oncology drug development.

Lantern Pharma (NASDAQ: LTRN) plans to release its Q1 2022 financial results on May 3, 2022, after market closure. Management will host a conference call at 4:30 PM ET to discuss these results and outline future milestones. Lantern Pharma utilizes its RADR^® A.I. platform in oncology drug development, focusing on genomically-targeted therapeutics. Currently, the company is developing four drug candidates and an ADC program spanning nine tumor targets, with a commitment to optimize patient outcomes.

Lantern Pharma (NASDAQ:LTRN) will be featured on The RedChip Money Report on Bloomberg TV on April 16 at 7 p.m. ET. This program, which reaches approximately 73 million U.S. households, focuses on small-cap investing and includes interviews with company executives and Wall Street analysts. Lantern Pharma utilizes its RADR® AI platform for oncology drug discovery, with a pipeline of four drug candidates and an ADC program targeting eight tumor types, including two in phase 2 trials.

Lantern Pharma (NASDAQ: LTRN) announced an extension of its share repurchase program through July 31, 2022, allowing for the acquisition of up to $7 million in common stock. Since November 2021, the program has seen the repurchase of 475,157 shares at a cost of approximately $3.4 million. An additional $3.6 million is available for future purchases. As of December 31, 2021, the company reported $70.7 million in cash and equivalents, indicating strong liquidity to support the buyback initiative.

Lantern Pharma (NASDAQ: LTRN) announced promising preclinical data for its drug candidate LP-184 at the upcoming AACR annual meeting, scheduled for April 8-13, 2022. LP-184 showed significant anti-tumor activity in brain metastases models from lung, skin, and breast cancers, achieving 6 times greater potency than standard therapies. This small molecule drug targets DNA in cancer cells, particularly beneficial for patients with CNS cancers due to its favorable blood-brain barrier permeability. The FDA has granted LP-184 Orphan Drug and Rare Pediatric Disease designations, expediting its path toward clinical trials.

Lantern Pharma (NASDAQ: LTRN) reported its financial results for Q4 and the fiscal year 2021, marking a pivotal year with significant growth and clinical advancements. The RADR® A.I. platform achieved a remarkable 1,000% growth, surpassing 18 billion data points, and is projected to exceed 25 billion by the end of 2022. The company plans to initiate multiple clinical trials in 2022, including the Phase 2 trial for LP-300 in non-small cell lung cancer. Lantern raised $69 million in 2021, extending its cash runway into 2025, while reporting a net loss of $12.4 million for the year.

Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, will hold a conference call on March 10, 2022, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2021 financial results. Management, led by CEO Panna Sharma, will provide insights into the company's operating performance and guidance on upcoming milestones. Lantern Pharma specializes in oncology drug development leveraging its RADR® A.I. platform to enhance patient targeting for drug trials. The call will also be available via a replay on their investor relations website.